These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 34365863)

  • 1. Treatment Outcomes of IL-17 Inhibitors in Hidradenitis Suppurativa: A Systematic Review.
    Kashetsky N; Mufti A; Alabdulrazzaq S; Lytvyn Y; Sachdeva M; Rahat A; Yeung J
    J Cutan Med Surg; 2022; 26(1):79-86. PubMed ID: 34365863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study.
    Frew JW; Navrazhina K; Grand D; Sullivan-Whalen M; Gilleaudeau P; Garcet S; Ungar J; Krueger JG
    J Am Acad Dermatol; 2020 Nov; 83(5):1341-1348. PubMed ID: 32416208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa.
    Stergianou D; Kanni T; Damoulari C; Giamarellos-Bourboulis EJ
    Expert Opin Biol Ther; 2024 Apr; 24(4):225-232. PubMed ID: 38602836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of biologics and JAK inhibitors in the management of moderate to severe Hidradenitis Suppurativa treatment: a scoping review.
    Guermazi D; Shah A; Yumeen S; Saliba E
    Arch Dermatol Res; 2024 May; 316(6):259. PubMed ID: 38795234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Off-label dermatologic uses of IL-17 inhibitors.
    Wu KK; Dao H
    J Dermatolog Treat; 2022 Feb; 33(1):41-47. PubMed ID: 32116066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents.
    Matusiak Ł; Szczęch J; Bieniek A; Nowicka-Suszko D; Szepietowski JC
    J Am Acad Dermatol; 2017 Apr; 76(4):670-675. PubMed ID: 28041632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-standing refractory hidradenitis suppurativa responded to a brodalumab monotherapy in a patient with psoriasis: A possible involvement of Th17 across the spectrum of both diseases.
    Yoshida Y; Oyama N; Iino S; Shimizu C; Hasegawa M
    J Dermatol; 2021 Jun; 48(6):916-920. PubMed ID: 33609416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials.
    Maarouf M; Clark AK; Lee DE; Shi VY
    J Dermatolog Treat; 2018 Aug; 29(5):441-449. PubMed ID: 29098911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brodalumab for severe hidradenitis suppurativa: a case of clinico-radiologic improvement and literature review.
    Vagnozzi E; Bruni M; Esposito M; Fargnoli MC
    J Dermatolog Treat; 2023 Dec; 34(1):2270091. PubMed ID: 37842732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ixekizumab in hidradenitis suppurativa in a psoriatic patient.
    Odorici G; Pellacani G; Conti A
    G Ital Dermatol Venereol; 2020 Dec; 155(6):788-789. PubMed ID: 30636397
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of hidradenitis suppurativa with brodalumab in biologic treatment failures: experiences from a specialty clinic.
    Kearney N; Hughes R; Kirby B
    Clin Exp Dermatol; 2023 Jul; 48(7):790-792. PubMed ID: 37017188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brodalumab for moderate-severe hidradenitis suppurativa: An open-label multicentric cohort study in real clinical practice.
    Osorio-Gómez GF; Ortiz-Álvarez J; Diaz-Ceca D; Guijarro-Sánchez C; Conejo-Mir Sánchez J; Fernández Crehuet P
    Australas J Dermatol; 2024 May; 65(3):254-259. PubMed ID: 38597096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum.
    Navrazhina K; Frew JW; Grand D; Williams SC; Hur H; Gonzalez J; Garcet S; Krueger JG
    Br J Dermatol; 2022 Aug; 187(2):223-233. PubMed ID: 35191018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The anti-inflammatory potency of biologics targeting tumour necrosis factor-α, interleukin (IL)-17A, IL-12/23 and CD20 in hidradenitis suppurativa: an ex vivo study.
    Vossen ARJV; Ardon CB; van der Zee HH; Lubberts E; Prens EP
    Br J Dermatol; 2019 Aug; 181(2):314-323. PubMed ID: 30657173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case Report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumab.
    Nikolakis G; Kreibich K; Vaiopoulos A; Kaleta K; Talas J; Becker M; Zouboulis CC
    F1000Res; 2021; 10():381. PubMed ID: 34540202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Regimen of IL-17A Inhibitor Secukinumab for the Remission of Severe Hidradenitis Suppurativa: Case Report.
    Gutierrez E; Issa N; Resnik B
    J Drugs Dermatol; 2022 Dec; 21(12):1358-1360. PubMed ID: 36468954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biology of Interleukin-17 and Novel Therapies for Hidradenitis Suppurativa.
    Sabat R; Gudjonsson JE; Brembilla NC; van Straalen KR; Wolk K
    J Interferon Cytokine Res; 2023 Dec; 43(12):544-556. PubMed ID: 37824200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.
    Kimball AB; Jemec GB; Yang M; Kageleiry A; Signorovitch JE; Okun MM; Gu Y; Wang K; Mulani P; Sundaram M
    Br J Dermatol; 2014 Dec; 171(6):1434-42. PubMed ID: 25040429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa.
    Aarts P; Dudink K; Vossen ARJV; van Straalen KR; Ardon CB; Prens EP; van der Zee HH
    Drugs; 2021 Aug; 81(12):1397-1410. PubMed ID: 34283386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn's disease.
    Berman HS; Villa NM; Shi VY; Hsiao JL
    J Dermatolog Treat; 2021 Mar; 32(2):261-263. PubMed ID: 31389737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.